165 studies found for:    new onset type 1 diabetes
Show Display Options
Rank Status Study
21 Terminated
Has Results
A Research Trial of Aralast in New Onset Diabetes (RETAIN)
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Aralast NP 45 mg dose;   Biological: Aralast NP 90 mg dose;   Biological: Aralast NP 180 mg dose
22 Completed Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Otelixizumab;   Biological: Placebo
23 Withdrawn The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients
Condition: Type 1 Diabetes
Interventions: Drug: Oral Cyclosporine and Oral Omeprazole;   Drug: Oral Omeprazole
24 Enrolling by invitation Effects of Gluten Free Diet on Type 1 Diabetes Mellitus in Children
Condition: Type 1 Diabetes Mellitus
Interventions: Other: Gluten Free Diet;   Other: Placebo
25 Completed Anti-Interleukin-1 in Diabetes Action
Condition: Type 1 Diabetes
Interventions: Drug: anakinra;   Drug: saline
26 Withdrawn A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Aralast NP;   Drug: Placebo
27 Active, not recruiting Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D
Condition: Type 1 Diabetes
Intervention: Drug: Ustekinumab
28 Completed
Has Results
Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: CTLA-4 Ig;   Other: Placebo
29 Active, not recruiting Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type I;   Diabetes Mellitus, Insulin-Dependent, 1;   Type 1 Diabetes Mellitus;   Insulin-Dependent Diabetes Mellitus 1;   IDDM
Interventions: Drug: Imatinib Mesylate;   Drug: Placebo (For imatinib mesylate)
30 Recruiting Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Tauroursodeoxycholic Acid (TUDCA);   Drug: Sugar Pill (placebo)
31 Completed Etanercept in New Onset Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Etanercept;   Drug: Placebo
32 Completed
Has Results
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
Condition: Type 1 Diabetes
Interventions: Drug: Atorvastatin;   Other: Placebo
33 Completed
Has Results
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Anti-CD3 mAb;   Other: Diabetes Standard of Care Treatment;   Dietary Supplement: Iron supplementation
34 Completed A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Twice Daily versus Three Times Daily Insulin Injections
35 Completed
Has Results
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Mycophenolate mofeteil (MMF);   Drug: Daclizumab (DZB);   Drug: Placebo control for Mycophenolate mofeteil (MMF);   Drug: Placebo control for Daclizumab (DZB)
36 Recruiting The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)
Condition: Type 1 Diabetes
Intervention: Other: Gluten-free diet
37 Completed
Has Results
Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Anti-CD20 (rituximab)
38 Withdrawn A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Condition: New Onset Type 1 Diabetes Mellitus
Intervention: Drug: Campath 1H® (Alemtuzumab)
39 Terminated
Has Results
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Secukinumab;   Drug: Placebo
40 Completed Effects of Recombinant Human Glutamic Acid Decarboxylase . . .
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: GAD-Alum;   Drug: Aluminum hydroxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years